Clinical Study
Influence of Peripheral Artery Disease and Statin Therapy on Apolipoprotein Profiles
Table 3
Apolipoprotein measures of subjects with peripheral artery disease (PAD) and controls. Values are means (standard deviation).
| | Variables | Control group () | PAD no statin group () | PAD statin group () | ANCOVA value | ΔAdjusted mean = control group − PAD groups | ΔAdjusted mean = PAD no statin group − PAD statin group |
| | ApoB (mg/dL) | 90.9 (12.3) | 93.8 (16.1) | 82.1 (19.2) | 0.085 | 1.7 | 12.0* | | ApoC-III (mg/dL) | 10.1 (3.0) | 10.1 (2.1) | 10.0 (3.4) | 0.890 | 0.4 | 0.0 | | ApoC-III HS (mg/dL) | 6.6 (2.7) | 6.9 (1.3) | 6.5 (2.0) | 0.507 | 0.6 | 0.2 | | ApoC-III HP (mg/dL) | 3.4 (1.3) | 3.1 (0.9) | 3.5 (3.0) | 0.823 | −0.2 | −0.3 | | ApoC-III ratio | 2.26 (1.32) | 2.37 (0.63) | 2.64 (1.46) | 0.552 | 0.19 | −0.42 | | Lp-B-II (mg/dL) | 90.4 (13.2) | 83.6 (17.9) | 81.5 (18.9) | 0.213 | 6.9 | 2.4 | | Lp-A-II:B:C:D:E (mg/dL) | 12.1 (5.8) | 23.0 (33.4) | 10.0 (4.7) | 0.079047 | −3.0 | 12.5* | | Lp-B:E + Lp-B:C:E (mg/dL) | 12.4 (4.5) | 22.6 (26.4) | 12.7 (5.6) | 0.066 | −4.2 | 9.5* | | Lp-B (mg/dL) | 59.8 (7.2) | 50.6 (20.0) | 54.8 (12.1) | 0.127 | 6.1* | −3.8 | | Lp-B:C (mg/dL) | 9.5 (4.0) | 20.0 (21.1) | 10.4 (4.8) | 0.013 | −5.1* | 9.4* | | Apo A1 (mg/dL) | 132.5 (16.5) | 134.8 (20.2) | 124.7 (18.9) | 0.156 | 5.4 | 9.2 | | Lp-A-I (mg/dL) | 34.8 (4.4) | 48.2 (37.9) | 32.5 (6.0) | 0.049 | −3.6 | 15.1* | | Lp-A-I:A-II (mg/dL) | 97.7 (12.9) | 87.0 (27.2) | 92.1 (15.5) | 0.134 | 8.8* | −5.3 | | B/A1 ratio | 0.69 (0.14) | 0.62 (0.13) | 0.66 (0.17) | 0.673 | 0.03 | −0.03 | | Lp-B/C-III HP ratio | 20.15 (8.46) | 18.33 (8.88) | 21.36 (9.34) | 0.461 | 1.78 | −3.54 |
|
|
.
|
